EGF and colorectal carcinoma: EGF signalling is a critical pathway for normal intestinal homeostasis, and amplification or mutations to the EGF receptor (EGFR) or downstream signalling components such as KRAS are frequent in CRC and render promising EGFR therapies ineffective (Moroni et al, 2005; Lievre et al, 2006; van Houdt et al, 2010; Misale et al, 2012).